Introduction
============

Bipolar disorder (BPD) affects ∼2.5% of the United States population aged 18 and older based on data from the population-based National Comorbidity Survey Replication.^[@bib1]^ The risk of BPD for a first-degree relative of an affected individual is 9%, and the concordance rate for monozygotic twins is 40--45%.^[@bib2]^ Relatives of BPD probands are also at an increased risk of other related psychiatric disorders, such as psychotic, anxiety, substance abuse and impulse control disorders.^[@bib1],\ [@bib2],\ [@bib3],\ [@bib4]^ With an overall heritability estimated at 80--90%,^[@bib2]^ these and other findings make clear that susceptibility to BPD has a very strong genetic basis that overlaps with the genetic susceptibility for other neuropsychiatric disorders.

The two most common subtypes of BPD are bipolar disorder I (BPD I) and bipolar disorder II (BPD II). The lifetime risks in the US population is 1% for BPD I and 1.1% for BPD II.^[@bib1]^ The clinical course of BPD I and BPD II differ in that BPD I patients exhibit one or more manic episodes while BPD II patients are characterized by recurrent depressive episodes.^[@bib2],\ [@bib3]^ Recurrence of manic/depressive episodes and associated disabilities is common[@bib5], [@bib6], [@bib7] and there exists no curative treatment. Although BPD I and BPD II have been shown to co-segregate within families,^[@bib2],\ [@bib8]^ the diverse clinical symptoms indicate that subtypes of the BPD phenotype exist and/or that phenotypic modifiers are involved.^[@bib9]^ The identification of BPD I and BPD II susceptibility genes may lead to more effective targets for therapy.

Several recent genome-wide genetic association studies and meta-analyses^[@bib2],\ [@bib10]^ have jointly analyzed BPD I and BPD II subjects,^[@bib10],\ [@bib11],\ [@bib12],\ [@bib13],\ [@bib14],\ [@bib15],\ [@bib16]^ or have focused only on BPD I subjects.^[@bib17],\ [@bib18],\ [@bib19]^ One motivation for grouping the subtypes is that it remains possible that BPD II is a milder form of BPD I as opposed to being a distinct disorder. However, genetic heterogeneity can reduce the power to detect susceptibility variants when samples of BPD I and BPD II are combined for analysis. For this study, we analyzed BPD I and BPD II separately to increase the likelihood of genetic homogeneity among cases.

A substantial body of evidence indicates a relationship between BPD and cyclic adenosine monophosphate (cAMP) signaling although the specific nature of the relationship remains obscure (reviewed in Gould and Manji^[@bib20]^ and Dwivedi and Pandy^[@bib21]^). Several studies on peripheral cells or post-mortem brain have reported that basal and receptor-activated adenylyl cyclase (AC) activities are increased in BPD patients.^[@bib22],\ [@bib23]^ Other studies have reported that the mood stabilizers lithium and carbamazepine interact directly or indirectly to attenuate the receptor-activation of ACs,^[@bib24],\ [@bib25],\ [@bib26],\ [@bib27],\ [@bib28],\ [@bib29]^ consistent with the possibility that an increased AC activity or activation is a biochemical phenotype associated with BPD. Several studies have shown that mRNA levels for Gαs, the stimulatory G-protein that couples with AC, are increased in peripheral cells of BPD patients.^[@bib30],\ [@bib31],\ [@bib32],\ [@bib33],\ [@bib34]^ Post-mortem analyses on brain have demonstrated an increased abundance of the Gαs protein, but not Gαi or Gαo,^[@bib32],\ [@bib30]^ and lithium has been found to decrease the abundance of mRNAs for several G-proteins.^[@bib35],\ [@bib36]^ Lithium may also decrease the coupling of receptors to G-proteins.^[@bib22],\ [@bib26],\ [@bib37],\ [@bib38],\ [@bib39]^ Post-mortem analyses have demonstrated a decreased level of the regulatory subunits for protein kinase A (PKA) in BPD,^[@bib40]^ with increased PKA activity observed in lymphocytes and platelets from BPD subjects.^[@bib41],\ [@bib42]^ Some substrates of PKA have been found to be hyperphosphorylated and increased PKA activity and immunoreactivity have been observed in post-mortem brain^[@bib43],\ [@bib44]^ and in peripheral cells^[@bib41],\ [@bib45],\ [@bib46],\ [@bib47]^ of BPD patients. Finally, the antidepressant rolipram inhibits cAMP phosphodiesterases (PDE) of the *dunce* class of PDEs (PDE4),^[@bib48]^ implicating this class of enzymes in the general state of depression. PDE4 expression is also altered in both BPD and schizophrenia.^[@bib49]^

Overall, the evidence strongly suggests that aberrant cAMP signaling is part of the spectrum of biochemical phenotypes associated with BPD. Because of the well-established roles of cAMP in regulating behavioral processes, we hypothesize that genetic variation in the cAMP pathway genes is associated BPD etiology. To test this hypothesis, and to identify the specific mutations within the signaling system that confer susceptibility to BPD, we focused our association study on the collection of genes comprising the cAMP signaling system, as opposed to testing a variety of genes representing many different signaling systems with unrelated functions in the central nervous system. These analyses detected associations of *PDE10A* with BPD I and of *DISC1* and *GNAS* with BPD II. In addition, significant associations were observed for interaction of variants in *DISC1* and *PDE4* for both BPD I and BPD II.

Materials and methods
=====================

Study samples
-------------

DNA samples were obtained from the Systemic Treatment Enhancement Program for BPD study (STEP-BPD). STEP-BPD was a national, longitudinal study designed to examine the effectiveness of BPD treatments in over 4000 patients with BPD.^[@bib50]^ Assignment of diagnosis was based on information derived from clinical assessment and psychiatric diagnostic interviews using the Affective Disorders Evaluation^[@bib50]^ and confirmed by the Mini International Neuropsychiatric Interview.^[@bib51]^ The affective disorders evaluation includes a modified version of the mood and psychosis modules of the Structured Clinical Interview from the American Psychiatric Association\'s, Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV; 1994). The interviews were administered by trained clinical specialists using DSM-IV criteria to establish diagnoses of BPD I, BPD II, BPD NOS, schizoaffective manic or BP type or cyclothymic disorder. Only subjects with BPD I or II diagnoses were included in the analysis. The National Institute of Mental Health-funded genetics repository (STEP-Genetics Repository) that created anonymous immortalized cell lines from participants in the STEP-BPD study provided genomic DNA samples for this study. Genomic DNA from controls selected to be of European-American descent and free of signs of depression was provided by the National Institute of Mental Health Genetic Repository. Controls in the repository were screened with the Composite International Diagnostic Interview to reduce the chances of inadvertently introducing susceptibility alleles for neuropsychiatric disorders into the control population. All subjects involved in both studies gave written, informed consent. As the subject and control DNA samples were both pre-existing and de-identified, this study was considered exempt human research by the Scripps Institutional and Baylor College of Medicine IRBs.

Single-nucleotide polymorphism (SNP) selection and genotyping
-------------------------------------------------------------

We selected 29 candidate genes representing biochemical functions that have been implicated in cAMP signaling. Cross-talk among signaling pathways is extensive in cellular physiology, which blurs their boundaries, so we selected genes that are widely recognized as comprising the conical cAMP signaling pathway so as to limit our set ([Table 1](#tbl1){ref-type="table"}). For these genes, tagSNPs were selected within each gene and flanking 10 kb, using HAPMAP data (European-American Utah residents with ancestry from Northern and Western Europe, which were collected by the Center d\'Etude du Polymorphisme Humaine (CEU)) using an *r*^2^⩾0.8, as a measure of linkage disequilibrium (LD) to capture variation within each gene and a minor allele frequency (MAF) ⩾0.05. A subset of 238 SNPs were selected to control for European substructure from a panel previously shown to distinguish different European populations.^[@bib52]^ One-thousand and fifty tagSNPs and 238 admixture SNPs were genotyped in 1742 cases and 1757 controls in addition to 58 duplicate samples using the Illumina Golden Gate array (Illumina, Inc., San Diego, CA, USA). Beadstudio software (Illumina) was used for allele detection and genotype calling.

Data quality control
--------------------

Data cleaning and analysis were performed using PLINK software.^[@bib53]^ Samples missing \>2% of their genotypes were excluded because missingness can be indicative of low-quality DNA and remaining genotypes may have high error rates. SNP markers were excluded if they were not successfully genotyped in \>95% of the samples, had a MAF \<1% or deviated from Hardy--Weinberg equilibrium with a *P*-value \<1 × 10^−6^ in controls. SNPs with deviation from Hardy--Weinberg equilibrium with a *P*-value of \<1 × 10^−3^ were flagged for follow-up and were also removed before SNP marker loci were imputed. Samples were also removed if they exhibited excess homozygosity or excess heterozygosity (\>4 s.d. from the median). In addition, identity-by-state statistics were calculated between samples to assess duplicates and to evaluate relatedness among individuals included in the study. Multidimensional scaling (MDS) was used to identify outliers using the population substructure SNPs. Samples were clustered with data from HAPMAP,^[@bib54]^ which was collected from individuals from CEU, Yoruba in Ibadan, Nigeria (YRI) and Japanese in Tokyo, Japan (JPT) and Han Chinese in Beijing, China (CBT). Samples were removed from further analysis if they deviated by \<3 s.d. from the median of the MDS component 1 and MDS component 2 within the CEU cluster. After data cleaning, 1728 controls, 1172 BPD I and 516 BPD II remained available for analysis.

To evaluate potential population substructure/admixture, λ, the median of the distribution of test statistics over the median expected under the null of no association^[@bib55]^ was calculated before and after sex, age and the first MDS component were included in the logistic regression model to control for potential confounding.

Association testing
-------------------

PLINK was used to perform logistic regression analyses under an additive model and was used to test for associations between single tagSNPs and BPD I and BPD II.^[@bib53]^ Haplotype analysis was performed using GenABEL^[@bib56]^ and Haplo Stats^[@bib57]^ using a sliding window of three SNPs. GenABEL was used to evaluate two-way interactions between tagSNPs in the cAMP signaling pathway. Findings were assessed for confounding with age and sex. The first MDS component calculated from the admixture SNPs for BPD I and for the analysis of BPD II sex was also included in the model to control for population substructure.

Imputation
----------

MACH was used to impute additional SNPs that were not genotyped in genes within the cAMP pathway.^[@bib58],\ [@bib59]^ It was not possible to impute additional SNPs for *PRKAR2B* and *PPP1CA* ([Table 1](#tbl1){ref-type="table"}) because of the limited number of genotyped SNPs. CEU phase haplotypes from HAPMAP phases 1 and 2^[@bib60]^ were used as templates to infer SNP markers that were not genotyped. The imputed SNPs with Rsq scores \>0.8 were analyzed in PLINK using the probability of each genotype in the analysis, which were analyzed as a dosage.

Single-nucelotide variant discovery
-----------------------------------

Thirty BPD I patients homozygous for the *PDE10A* region 1 risk haplotype were randomly selected for single-nucleotide variant (SNV) variant discovery. An ∼23 kb region (chr6: 166063714--166040354) was amplified as three long-range PCR products using the Takara LA polymerase (Fisher Scientific, Pittsburgh, PA, USA). Nested PCR products ranging in size from 2--3 kb were amplified from the long-range PCR products using the Roche high fidelity and GC rich polymerase systems (Branchburg, NJ, USA). The PCR products were then sequenced using Sanger methodology (Genewiz, South Plainfield, NJ, USA), analyzed for variants using the Sequencher v.5 software (Gene Codes Corporation, Ann Arbor, MI, USA), and compared with a reference sequence (UCSC genome browser, Feb 2009 GRCh37/hg19 build). All coding exons of *PDE10A* isoforms 1 and 2 (Genbank NM001130690.1 and NM 006661.2) were also sequenced and analyzed to rule out any obvious non-synonomous amino acid or splice site changes that could be disease associated.

SNV genotyping and analysis
---------------------------

All variants from the reference sequence were investigated using dbSNP build 135. Any novel variants, not reported in dbSNP, were analyzed using Taqman SNP genotyping assays (Applied Biosystems, Carlsbad, CA, USA). The following numbers of randomly chosen individuals were analyzed for SNV allele frequencies: 807 BD I, 192 BD II and 801 controls. Taqman assays were performed in a 384-well plate format according to manufacturer\'s instructions on a 7900HT Fast real-time PCR instrument (Applied Biosystems).

Rare variant analysis was restricted to those SNVs with MAF \<1%. We previously demonstrated that directly combining sequence and genotype data can lead to inflated type I errors in two-stage association studies.^[@bib61]^ This experimental design involves sequencing a portion of the cases to discover variants followed by genotyping the identified variants in the remaining sample. We therefore developed a likelihood-based method named SEQCHIP, for integrating sequencing and genotype data from two-stage association studies. It corrects for the genotypes of sequenced BPD I and BPD II cases, so that the corrected sequenced genotypes follow the same distribution as that of the genotyped samples.^[@bib62]^ The corrected genotypes can then be analyzed by existing rare variant tests, which were shown to have correct type I errors.^[@bib62]^ More specifically, the association analyses described here utilized the ANRV (aggregated number of rare variants),^[@bib63]^ the WSS (weighted sum statistics)^[@bib64]^ and the VT (variable threshold)^[@bib65]^ tests.

Results
=======

Nine hundred and eighty-eight tagSNPs that met quality control criteria within 29 candidate genes ([Table 1](#tbl1){ref-type="table"}) were tested for associations using 1172 BPD I cases, 516 BPD II cases and 1728 controls. There was evidence of population substructure in the sample comparing the controls to the BPD cases (*λ*=1.11). The addition of one MDS component calculated from the admixture SNPs decreased *λ* to 1.03.

None of the association tests of the tagSNPs with either BPD I or BPD II reached genome-wide significance (*P*\<5 × 10^−8^). Association results for tagSNPs with *P*\<0.01 with BPD I and BPD II are shown in [Table 2](#tbl2){ref-type="table"}. Those SNPs that displayed a nominal significance level of *P*\<0.05 are shown in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. An additional 2675 tagSNPs were imputed in the cAMP signaling pathway genes using the 988 tagSNPs that passed quality control ([Table 1](#tbl1){ref-type="table"}). All imputed SNPs were analyzed and results of imputed SNPs with *P*\<0.05 are included in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}.

Twelve different tagSNPs in the *PDE10A* gene were associated with BPD I at *P*\<0.01, including rs2983521 with an odds ratio (OR) of 1.3, a 95% confidence interval ranging from 1.1 to 1.5, and a *P*=9.3 × 10^−5^ ([Table 2](#tbl2){ref-type="table"}). Seven of the *PDE10A* tagSNPs, such as rs1033701 (OR=1.2, *P*=5.4 × 10^−4^), that associated with BPD I with ORs ranging from 1.2 to 1.3 (*P*\<0.01) were found to be in moderate LD (*r*^2^\>0.3). An additional 333 SNPs were imputed in *PDE10A* ([Figure 1](#fig1){ref-type="fig"}, panel a). Our analyses of these imputed SNPs indicated that an additional seven SNPs were associated with BPD I at *P*\<0.01 ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). One example is rs2983516, with OR of 1.3 and *P*=5.4 × 10^−5^.

The analysis of *PDE10A* haplotype windows revealed a series of haplotypes that were associated with BPD I ([Figure 1](#fig1){ref-type="fig"}, panel b). Two regions in *PDE10A* (region 1 at 166.1 Mb and region 2 at 165.8 Mb) were associated with BPD I. Region 1 is large non-coding region within intron 1 that may be important for the regulation of *PDE10A* expression. Because of this possibility and the large number of associated tagSNPs that fell within this region, SNV identification was focused to a 23-kb region on 30 BPD I patients homozygous for the region 1, minor allele risk SNPs ([Figure 2](#fig2){ref-type="fig"}).

Thirteen SNVs were identified among these BPD I cases. These SNVs were genotyped in 999 cases (807 BPD I and 192 BPD II) in addition to 801 controls. Subsequent analysis was restricted to the eight novel SNVs with a MAF \<1% to exclude common polymorphisms ([Table 3](#tbl3){ref-type="table"}). Interestingly, the SNVs chr6:166054721 insA and chr6: 166046780_166046778 delATT were found simultaneously in 2 of the 807 BD I cases genotyped. These SNVs are in complete LD in all individuals genotyped. As the newly identified variants are individually rare, they were aggregated and jointly analyzed to determine their collective effect. When only genotyped samples were analyzed, the *P*-values were P(ANRV)=3.9 × 10^−2^, P(WSS)=7.1 × 10^−2^ and P(VT)=8.0 × 10^−2^. When SEQCHIP was used to integrate both sequence and genotype data, the *P*-values were P(ANRV)=2.2 × 10^−2^, P(WSS)=2.0 × 10^−3^ and P(VT)=3.0 × 10^−2^. Using SEQCHIP, genotype and sequence data can be more efficiently utilized and a stronger association signal was identified.

One tagSNP in *DISC1*, rs10495310, was associated with BPD I ([Table 2](#tbl2){ref-type="table"}). However, three tagSNPs in *DISC1* were associated with BPD II with *P*\<0.01 ([Table 2](#tbl2){ref-type="table"}). Two of the *DISC1* tagSNPs, rs2812391 and rs10495310, conferred increased risk of BPD II with ORs of 1.2 and 1.4 for each SNP, whereas the third SNP, rs4658954, conferred decreased risk with an OR of 0.8. The tagSNPs rs2812391 and rs10495310 are in mild LD (*r*^2^=0.28), whereas both are not in LD with rs4658954 (*r*^2^=0.01 and *r*^2^=0.02, respectively). Furthermore, an additional 335 SNPs were imputed in *DISC1* ([Figure 2](#fig2){ref-type="fig"}, panel a) and one SNP, rs3082, was associated with BPD II with an OR of 1.3 (*P*=5.5 × 10^−3^). *DISC1* haplotype analysis ([Figure 2](#fig2){ref-type="fig"}, panel **b**) indicated that two regions (region 1 at 231.9 Mb and region 2 at 232.1 Mb) were associated with BPD II. The *DISC1* region 1 haplotype consisting of rs10495310, rs4658945 and rs16854967 had an empirical global *P*=1.7 × 10^−3^ for its association with BPD II. The *DISC1* region 2 haplotype consisting of rs12137417, rs9431736 and rs7548491 had an empirical global *P*=3.9 × 10^−2^.

Two tagSNPs in *GNAS*, rs6064714 and rs6026565, were associated with BPD I at *P*\<0.01 ([Table 2](#tbl2){ref-type="table"}). However, *GNAS* appeared to have a stronger association with BPD II in this study with three tagSNPs associated at *P*\<0.01 ([Table 2](#tbl2){ref-type="table"}). Two of tagSNPs conferred increased risk (rs35113254 and rs6026565) for BPD II, whereas the third (rs6064714) conferred decreased risk. The SNPs rs35113254 and rs6026565 are in moderate LD (*r*^2^=0.35) but are both not in LD with rs6064714 (*r*^2^=0.04 and *r*^2^=0.01, respectively). The rs35113254 SNP in *GNAS* was the most significantly associated tagSNP representing the cAMP signaling pathway with *P*=5.8 × 10^−5^ with an OR of 1.4 for BPD II. Similarly, an additional 18 SNPs were imputed in *GNAS* ([Figure 3](#fig3){ref-type="fig"}, panel a) and an additional SNP, rs6026560, was associated with BPD II with an OR of 0.7 (*P*=1.4 × 10^−4^). Haplotype analysis in *GNAS* indicated a region around 5.74 Mb that was associated with BPD II ([Figure 4](#fig4){ref-type="fig"}, panel b). This region overlaps with the results from imputed and genotyped SNPs.

Single tagSNPs in *PDE4B* (rs4384209), *PRKACB* (rs600674), *GNAI2* (rs2282751), *PDE4D* (rs17741863) and *ADCY8* (rs13278912) were also associated with BPD I with *P* \<0.01. Additionally, imputed SNPs in *PRKACB* (four imputed SNPs), *PDE4D* (nine imputed SNPs) and *ADCY8* (one imputed SNP) were associated with BPD I at *P*\<0.01 ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). Numerous haplotype windows had *P*\<0.05, however, only *PDE10A, DISC1* and *GNAS* had notable peaks like those presented in [Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"} panel (b) for these genes.

Results for all two-way interactions between SNPs in the cAMP signaling pathway with *P*\<0.0001 are presented in [Supplementary Table 4](#sup1){ref-type="supplementary-material"}. A total of 29 two-way tagSNP interactions with BPD I and 34 two-way tagSNP interactions with BPD II had *P*\<0.0001. For both BPD I and BPD II, several interactions between *PDE4* and *DISC1* SNPs were significant. *PDE4D* tagSNP rs4699931 and *ADCY8* tagSNP rs928136 interaction was associated with an increased OR~interaction~ of 3.65 for BPD I (*P*=1.06 × 10^−5^), while *PDE4B* tagSNP rs12404118 and *DISC1* tagSNP rs823162 interaction was associated with an increased OR~interaction~ of 3.53 for BPD II (*P*=5.47 × 10^−5^).

Discussion
==========

This study represents the first genetic association study of BPD I and BPD II using dozens of genes comprising the cAMP signaling pathway. Collectively, our results indicate that some of the analyzed SNPs in several genes of the pathway are in LD with causal variants for BPD I and BPD II. Furthermore, the SNV discovery aspect of our study has identified new variants in the *PDE10A* gene of BPD subjects that may be causally related to the disorder. Our genetic studies are consistent with prior biochemical studies implicating cAMP signaling in BPD, and highlight specific genes and SNVs that could be of major importance for these disorders.

We employed three noteworthy strategies for elucidating the genetic basis for susceptibility to BPD. First, our association study utilized 29 candidate genes representing a single-signaling pathway. The hypothesis underlying this strategy was that if one gene in the signaling pathway is involved, then casual variants in other genes of the same pathway are likely involved as well. We recognize that there exist known and obvious intersections and cross-talk between the cAMP signaling pathway and other signaling pathways, but we selected genes that are widely recognized as comprising the canonical cAMP signaling pathway in order to sample a defined and limited set of genes. A 'molecular pathway hypothesis\' as contrasted with a 'single gene hypothesis,\' may account for the genetic heterogeneity of neuropsychiatric disorders in general and the marked difficulty in discovering genetic variants that have prominent roles in these disorders. It can also explain heterogeneity in clinical phenotypes or severity within a disorder, since a variant in an *AC* gene, for instance, might have largely overlapping but some distinct phenotypic effects compared with a variant in cAMP PDE. The interaction analyses were motivated by the 'molecular pathway hypothesis\' as functional variants in two molecular functions of a pathway could produce a more pronounced effect than either single functional variant. For instance, the relatively large OR produced by considering an interaction between *PDE4D* and *ADCY8* for BPD I ([Supplementary Table 4](#sup1){ref-type="supplementary-material"}) could be due to a functional variant that decreases *PDE4D* activity synergistically interacting with one that increases *ADCY8* activity. Similarly, an interaction between variants in *PDE4B* and *DISC1* for BPD II could be because of two separate functional variants that have synergistic effects on signaling. These ideas remain speculative and depend on the sign and magnitude that the functional variants have on the molecular factors involved.

Second, the choice of candidate molecular pathways considered the known and major role of the signaling pathway in the regulation of behavior in model systems. Genetic studies of learning and memory, circadian rhythms and other behaviors in model systems like *Drosophila* and the mouse have identified hundreds of genes that have behavioral roles. A good example of this is the cAMP PDE encoded by the *Drosophila dunce* gene, which is involved in learning and memory in *Drosophila*,^[@bib66]^ but whose human counterparts are involved in mood regulation^[@bib48]^ and schizoaffective disorders.^[@bib67]^ Candidate genes selected from the human homologs of genes with known behavioral roles in model systems should provide an extremely effective filter in gene discovery for neuropsychiatric disorders.

Third, we followed-up the initial association study with SNV discovery in the vicinity of the associated *PDE10A* tagSNPs that identified additional variants that may be causally involved in BPD. This required the development of a new method for integrating information from sequencing projects in a cost effective way. Using this method, named SEQCHIP, we were able to combine the sequencing data from 30 BPD I patients used for discovery with the data from the follow-up genotyping in a larger subset while accounting for potential bias. This approach was used to identify potentially causal variants that are tagged by the genotyped SNPs. When the data are integrated by SEQCHIP, all rare variant tests have correct type I errors. The genetic information from both sequence and genotype data were efficiently utilized, and therefore, more significant association signals were identified.

Suggestive evidence from other studies is consistent with the possibility that these newly discovered SNVs are involved in BPD. A recent RNA sequencing study employing human prefrontal cortex suggested that two of these SNVs (chr6:166052752 C\>G and chr6: 166046780_166046778 delATT) may be associated with novel PDE10A transcripts.^[@bib68]^ Another study performing chromatin immunoprecipitation sequencing on neuronal cells from human prefrontal cortex tissue showed that SNVs, chr6:166058713 C\>T, chr6:166056798 A\>T and chr6: 166046780_166046778 delATT are associated with an enriched H3K4me3 signal, suggesting that they participate in the transcriptional regulation of PDE10A.^[@bib69]^ Although this preliminary evidence must be confirmed in human tissue expressing PDE10A, it does suggest that these variants may have a role in PDE10A protein expression.

Our study highlights the association of *PDE10A* with BPD I. Of related and high interest is the observation that the *PDE10A* gene resides at 6q26, within one of the four leading linkage regions for BPD.^[@bib2]^ The PDEs degrade cAMP and/or cyclic guanosine monophosphate to their 5′-AMP and 5′-GMP counterparts and members of this large enzyme family are known to have broad roles in controlling behavioral output in diverse organisms from flies to humans.^[@bib66],\ [@bib70]^ The family member *PDE10A* codes for an 89-kDA protein capable of hydrolyzing both cAMP and cyclic guanosine monophosphate that is expressed in the brain and preferentially in the basal ganglia.^[@bib71],\ [@bib72],\ [@bib73],\ [@bib74]^ This expression pattern paired with basal ganglia dysfunction in schizophrenia have led to robust efforts in identifying drugs that target PDE10A for the treatment of schizophrenia.^[@bib75],\ [@bib76],\ [@bib77]^ The association of *PDE10A* with BPD I expands the potential range over which PDE10A drugs might exhibit efficacy.

The gene disrupted in schizophrenia 1 (*DISC1*) was first implicated in psychiatric disorders after a t(1;11) translocation was discovered in a large Scottish family cosegregating with schizophrenia, BPD and recurrent major depression.^[@bib78],\ [@bib79]^ The *DISC1* region has subsequently been implicated with bipolar spectrum traits in several candidate gene association studies.^[@bib80],\ [@bib81],\ [@bib82],\ [@bib83],\ [@bib84],\ [@bib85]^ The selection of tagSNPs has varied from study to study so we were unable to compare the precise haplotype windows between this and other studies. In addition, the majority of studies failed to control for population admixture and in most cases termed a *P*-value of less than nominal significance (*P*-value \<0.05) as significant. Relative to individual tagSNP associations that have been reported, Perlis *et al.*^[@bib86]^ observed an association between rs1934909 and BPD. We observed an association between this tagSNP and BPD II (OR=0.8, *P*=0.01) but not BPD I cases ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Similarly, Schosser *et al.*^[@bib83]^ observed an increased prevalence of BPD for carriers of the minor allele of rs2492367. We observed an association between this SNP and BPD II but not BPD I (OR=0.8, *P*=0.03).

It seems highly likely given the complexity of the DISC1 protein and it\'s multiple molecular roles^[@bib87]^ that there exist multiple functional variants linked to the various tagSNPs used in this and other studies. DISC1 interacts with several key proteins in pathways that have important roles in neuronal migration, dendritic organization and neurogenesis in addition to cAMP signaling.^[@bib67],\ [@bib87],\ [@bib88],\ [@bib89],\ [@bib90],\ [@bib91],\ [@bib92]^ The binding sites for interacting proteins are plausible regions for multiple susceptibility regions as are regions of the protein that modify binding. This could underlie the *DISC1* and *PDE4* tagSNP interactions observed to be significantly associated with BPD I and BPD II in this study. Furthermore, *DISC1* variants in intronic regions may influence *DISC1* mRNA and subsequent protein levels that also could interfere with key pathways. Indeed, Maeda *et al.*^[@bib93]^ demonstrated reduced *DISC1* mRNA levels in lymphoblasts from BPD subjects compared with unaffected family controls. Thus, it is plausible that multiple genetic variants in LD with *DISC1* tagSNPs exist that alter protein function or mRNA levels that influence susceptibility to neuropsychiatric disorders. Identifying these variants and characterizing their effect on DISC1 molecular functions may provide useful information for the development of novel therapeutics for bipolar spectrum traits.

The guanine nucleotide-binding protein, α-stimulating polypeptide 1 (*GNAS*) encodes the Gαs subunit of heterotrimeric G-proteins with Gαs activating AC for increased synthesis of cAMP. Although the exact mode of action of lithium in treating BPD remains elusive, there exists evidence that lithium decreases G-protein subunit mRNA levels.^[@bib35]^ Moreover, it has been speculated that lithium functions to stabilize the inactive conformation of G-proteins.^[@bib94]^ *GNAS* variants, like rs6064714 and rs6026565, may be tagging functional variants in BPD I patients that interfere with Gαs\' role in regulating cAMP signaling.

It is of interest that SNPs representing certain genes, such as *PDE4B* and *PDE10A*, were found as associated with BPD I but not BPD II. It is possible that this represents an authentic genetic difference between the two BPD subtypes. However, it could also be that the power to detect the association was stronger with the BPD I population, given that the BPD I population was twice the size of the BPD II population. If the data reflect authentic genetic differences between the two subtypes, they could be important to the pharmacogenetics of BPD treatment. For instance, perhaps an altered regulation of PDE10A, specific to BPD I, is most related to full-blown mania associated with BPD I. Drugs with PDE10A action may then have a primary effect on mania.

Overall, this study provides insight into the variation that exists in genes in the cAMP signaling pathway and the association of that variation with BPD I and BPD II. Key regions were identified in *PDE10A*, *GNAS* and *DISC1* that are associated with BPD I and BPD II. The effect size for these associations was modest, as observed in most other genetic association studies for neuropsychiatric disorders. Our study also illustrates the feasibility of performing large candidate gene or GWAS (genome-wide associated studies) studies followed by targeted direct sequencing to uncover novel, rare SNVs that may be associated with disease.
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![*PDE10A* association with bipolar disorder I (BPD I). The points in panel (**a**) represent genotyped (black circles) and imputed (open triangles) single-nucleotide polymorphisms (SNPs) and their probability of association with BPD I. Panel (**b)** illustrates probability as a sequential sliding window with three SNPs per window for the genotyped SNPs (empirical haplotype) and all SNPs (haplotype). The results were adjusted for age and population substructure. Panel (**c**) shows the structure of the *PDE10A* gene aligned with panels A and B with exons represented by bars. The direction of transcription, 5′→3′ is from right to left in this figure.](tp201292f1){#fig1}

![*PDE10A* region 1 risk linkage disequilibrium (LD) plot. Shading and values in cells correspond to *r*^2^ values between single-nucleotide polymorphism (SNP) pairs. The SNPs within region 1 and with odds ratio (OR) \>1.0 were used to define the boundaries for subsequent sequencing.](tp201292f2){#fig2}

![*DISC1* association with bipolar disorder II (BPD II). The points in panel (**a**) represent genotyped. (black circles) and imputed (open triangles) single-nucleotide polymorphisms (SNPs) and their probability of association with BPD II. Panel (**b)** illustrates probability as a sequential sliding window with three SNPs per window for the genotyped SNPs (empirical haplotype) and all SNPs (haplotype). The results were adjusted for age and population substructure. Panel (**c**) shows the structure of the *DISC1* gene aligned with panels (**a**) and (**b**) with exons represented by bars. The direction of transcription, 5′→3′ is from left to right in this figure.](tp201292f3){#fig3}

![*GNAS* association with bipolar disorder II (BPD II). The points in panel (**a**) represent genotyped. (black circles) and imputed (open triangles) single-nucleotide polymorphisms (SNPs) and their probability of association with BPD II. Panel (**b**) illustrates probability as a sequential sliding window with three SNPs per window for the genotyped SNPs (empirical haplotype) and all SNPs (haplotype). Panel (**c**) shows the structure of the *GNAS* gene aligned with panels (**a**) and (**b**) with exons represented by bars. The direction of transcription, 5′→3′ is from right to left in this figure.](tp201292f4){#fig4}

###### Cyclic AMP signaling pathway genes for which tagSNPs were genotyped

  *Gene symbol*   *Gene name*                                                                               *Location*      *tagSNPs pre-QC*   *tagSNPs post-QC*   *Imputed SNPs*   *Gene size (kb)*
  --------------- ----------------------------------------------------------------------------------------- --------------- ------------------ ------------------- ---------------- ------------------
  *GNAI3*         Guanine nucleotide-binding protein (G-protein), alpha inhibiting activity polypeptide 3   1p13            14                 12                  27               47
  *PDE4B*         Phosphodiesterase 4B, cAMP-specific (phosphodiesterase E4 dunce homolog, *Drosophila*)    1p31            100                93                  361              582
  *PRKACB*        Protein kinase, cAMP-dependent, catalytic, beta                                           1p36.1          21                 21                  66               160
  *DISC1*         Disrupted in schizophrenia 1                                                              1q42.1          148                137                 335              339
  *PPP1CB*        Protein phosphatase 1, catalytic subunit, beta isoform                                    2p23            9                  8                   30               51
  *CREB1*         cAMP responsive element binding protein 1                                                 2q34            6                  5                   28               69
  *GNAI2*         Guanine nucleotide-binding protein (G-protein), alpha inhibiting activity polypeptide 2   3p21            4                  4                   56               33
  *PRKAR2A*       Protein kinase, cAMP-dependent, regulatory, type II, alpha                                3p21.3-p21.2    3                  3                   14               97
  *PDE4D*         Phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog*, Drosophila*)    5q12            226                219                 560              1519
  *PPP2CA*        Protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform                     5q31.1          2                  2                   10               30
  *PDE10A*        Phosphodiesterase 10A                                                                     6q26            149                140                 333              331
  *ADCY1*         Adenylate cyclase 1 (brain)                                                               7p13-p12        33                 30                  59               149
  *PRKAR1B*       Protein kinase, cAMP-dependent, regulatory, type I, beta                                  7p22            1                  1                   NA               22
  *GNAI1*         Guanine nucleotide-binding protein (G-protein), alpha inhibiting activity polypeptide 1   7q21            30                 29                  56               85
  *PRKAR2B*       Protein kinase, cAMP-dependent, regulatory, type II, beta                                 7q22            20                 20                  80               117
  *ADCY8*         Adenylyl cyclase 8 (brain)                                                                8q24            116                108                 281              260
  *PPP1CA*        Protein phosphatase 1, catalytic subunit, alpha isoform                                   11q13           3                  3                   NA               23
  *PPP1CC*        Protein phosphatase 1, catalytic subunit, gamma isoform                                   12q24.1-q24.2   4                  3                   8                23
  *GNAO1*         Guanine nucleotide10-binding protein, alpha activating activity polypeptide O             16q13           55                 49                  125              166
  *AKAP10*        Protein kinase A anchoring protein 10                                                     17p11.1         6                  6                   22               72
  *NF1*           Neurofibromin, type1                                                                      17q11.2         8                  7                   94               283
  *PPP1R1B*       Protein phosphatase 1, regulatory (inhibitor) subunit 1B                                  17q12           2                  2                   2                10
  *PRKAR1A*       Protein kinase, cAMP-dependent, regulatory, type I, alpha                                 17q23-q24       8                  8                   25               39
  *PPP4R1*        Protein phosphatase 4, regulatory subunit 1                                               18p11.22        27                 26                  41               68
  *PRKACA*        Protein kinase, cAMP-dependent, catalytic, alpha                                          19p13.1         1                  1                   1                26
  *PDE4C*         Phosphodiesterase 4C, cAMP-specific (phosphodiesterase E1 dunce homolog, *Drosophila*)    19p13.11        8                  7                   12               47
  *PDE4A*         Phosphodiesterase 4A, cAMP-specific (phosphodiesterase E2 dunce homolog, *Drosophila*)    19p13.2         3                  3                   1                49
  *GNAS*          GNAS complex locus                                                                        20q13.3         31                 31                  18               71
  *GNAZ*          Guanine nucleotide-binding protein(G-protein), alpha Z polypeptide                        22q11.22        12                 10                  40               55

Abbreviation: cAMP, cyclic adenosine monophosphate; NA, not applicable; SNP, single-nucleotide polymorphism.

###### TagSNP associations with BPD I and BPD II at *P*\<0.01

  *Chromosome*   *SNP*        *Position (GRCh37/hg19)*   *MAF*   *OR*   *95% CI*     P              *Gene*
  -------------- ------------ -------------------------- ------- ------ ------------ -------------- ----------
  *BPD I*                                                                                            
   1             rs4384209    66279125                   0.23    1.2    (1.1--1.4)   1.2 × 10^−3^   *PDE4B*
   1             rs600674     84701251                   0.20    0.8    (0.7--0.9)   6.5 × 10^−3^   *PRKACB*
   1             rs10495310   231918776                  0.11    1.3    (1.1--1.5)   1.8 × 10^−3^   *DISC1*
   3             rs2282751    50291785                   0.14    1.2    (1.1--1.4)   6.1 × 10^−3^   *GNAI2*
   5             rs17741863   58858302                   0.10    1.3    (1.1--1.5)   4.0 × 10^−3^   *PDE4D*
   6             rs9459417    165837992                  0.13    0.8    (0.7--0.9)   8.4 × 10^−3^   *PDE10A*
   6             rs470922     165844311                  0.31    0.8    (0.7--0.9)   3.1 × 10^−3^   *PDE10A*
   6             rs4709082    166040621                  0.39    1.2    (1.1--1.3)   8.3 × 10^−3^   *PDE10A*
   6             rs1033701    166040859                  0.28    1.2    (1.1--1.4)   5.4 × 10^−4^   *PDE10A*
   6             rs9459464    166042705                  0.42    1.2    (1.1--1.3)   1.7 × 10^−3^   *PDE10A*
   6             rs1079418    166047034                  0.31    1.2    (1.1--1.3)   2.7 × 10^−3^   *PDE10A*
   6             rs9459465    166048868                  0.23    0.8    (0.7--0.9)   2.7 × 10^−3^   *PDE10A*
   6             rs2983517    166051731                  0.27    1.2    (1.1--1.4)   1.0 × 10^−3^   *PDE10A*
   6             rs2983521    166057203                  0.24    1.3    (1.1--1.5)   9.3 × 10^−5^   *PDE10A*
   6             rs9365899    166062379                  0.31    0.8    (0.7--0.9)   2.3 × 10^−3^   *PDE10A*
   6             rs3008049    166063617                  0.32    1.2    (1.1--1.4)   1.1 × 10^−3^   *PDE10A*
   6             rs10214709   166066893                  0.24    0.8    (0.7--1.0)   8.2 × 10^−3^   *PDE10A*
   8             rs13278912   132002770                  0.16    1.2    (1.1--1.4)   8.1 × 10^−3^   *ADCY8*
   20            rs6064714    57414140                   0.15    0.8    (0.7--0.9)   1.5 × 10^−3^   *GNAS*
   20            rs6026565    57439308                   0.10    1.3    (1.1--1.5)   1.7 × 10^−3^   *GNAS*
                                                                                                    
  *BPD II*                                                                                          
   1             rs2812391    231911976                  0.27    1.2    (1.1--1.5)   5.3 × 10^−3^   *DISC1*
   1             rs10495310   231918776                  0.11    1.4    (1.1--1.7)   3.2 × 10^−3^   *DISC1*
   1             rs4658954    231979357                  0.37    0.8    (0.7--0.9)   4.0 × 10^−3^   *DISC1*
   20            rs6064714    57414140                   0.15    0.7    (0.6--0.9)   1.1 × 10^−3^   *GNAS*
   20            rs35113254   57435532                   0.23    1.4    (1.2--1.6)   5.8 × 10^−5^   *GNAS*
   20            rs6026565    57439308                   0.10    1.4    (1.1--1.7)   6.9 × 10^−3^   *GNAS*

Abbreviations: BPD I, bipolar disorder I; BPD II, bipolar disorder II; CI, confidence interval; MAF, minor allele frequency; OR, odds ratio; SNP, single-nucleotide polymorphism.

###### *PDE10A* Region 1 SNVs with MAF \<0.01

  *Observed SNP*    *Chromosome*       *Position*        *A1*   *A2*   *Controls (N=801)*   *BPD cases (N=999)*   *BPD I cases (N=807)*
  ---------------- -------------- --------------------- ------ ------ -------------------- --------------------- -----------------------
  C\>T                   6              166042004         T      C             0                 0.000502               0.0006219
  G\>A                   6              166045644         A      G          0.000624             0.001505               0.001863
  T\>G                   6              166046710         G      T          0.000625             0.001503               0.001861
  delATT                 6         166046780_166046778    A      T             0                 0.001001               0.001239
  C\>G                   6              166052752         G      C          0.000624             0.001001               0.001239
  insA                   6              166054721         A      T             0                 0.001001               0.001239
  A\>T                   6              166056798         T      A          0.000624             0.003504               0.003717
  C\>T                   6              166058713         T      C             0                 0.000502               0.0006203

Abbreviations: BPD, bipolar disorder; MAF, minor allele frequency; SNP, single-nucleotide polymorphism; SNV, single-nucleotide variant.

Position: February 2009 (GRCh37/hg19) build physical position. A1: minor allele. A2: major allele.
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